Uematsu Masaki, Ohsawa Ikuroh, Aokage Toshiyuki, Nishimaki Kiyomi, Matsumoto Kouji, Takahashi Hiroshi, Asoh Sadamitsu, Teramoto Akira, Ohta Shigeo
Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Graduate School of Medicine, Nippon Medical School, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki, Kanagawa, Japan.
J Neurooncol. 2005 May;72(3):231-8. doi: 10.1007/s11060-004-2353-3.
Survivin has been identified as a protein expressed in cancer cells and a member of the inhibitor-of-apoptosis protein family. Recent studies suggest that the expression of survivin increases during the G2/M phase of the cell cycle, and may be used in clinical prognosis. We examined whether survivin expression in human gliomas would be a correlative of prognosis.
We prepared polyclonal anti-survivin serum to establish a survivin index for stained sections, using an immunohistochemical procedure, according to the method used for scoring MIB-1 index, and then stained 29 paraffin-embedded sections from surgical specimens of 29 patients who were classified into three grades of World Health Organization with the mean age of low grade astocytoma (grade II) being 34.7; anaplastic astrocytoma (grade III), 48.8; and glioblastoma multiform (grade IV), 58.4.
On staining with the anti-survivin antiserum, all specimens contained positive cells, but the survivin index was heterogeneous among grades. The mean percentage of immunoreactive cells in each specimen was 70.0 (SD 18.2) in grade II, 81.3 (16.5) in grade III, and 85.0 (13.6) in grade IV. Then we compared the survivin index to the MIB-1 index and found that in low-grade gliomas (grade II and III), the difference in survival times between the high and low survivin indexes was significant (P=0.007), whereas that between the high and low MIB-1 indexes was not significant (P=0.092). ONCLUSION: Survivin is more sensitive marker than MIB-1 for the evaluation of low-grade gliomas in that it helps to predict patient survival. Much larger glioma patient series are needed to validate the findings of our limited study.
生存素已被鉴定为一种在癌细胞中表达的蛋白质，是凋亡抑制蛋白家族的成员。最近的研究表明，生存素的表达在细胞周期的G2/M期增加，并且可能用于临床预后评估。我们研究了人类胶质瘤中生存素的表达是否与预后相关。
我们制备了多克隆抗生存素血清，按照用于计算MIB-1指数的方法，采用免疫组织化学程序为染色切片建立生存素指数，然后对29例患者手术标本的29张石蜡包埋切片进行染色，这些患者被分为世界卫生组织的三个级别，低级别星形细胞瘤（II级）的平均年龄为34.7岁；间变性星形细胞瘤（III级）为48.8岁；多形性胶质母细胞瘤（IV级）为58.4岁。
用抗生存素抗血清染色时，所有标本均含有阳性细胞，但生存素指数在不同级别之间存在差异。II级每个标本中免疫反应性细胞的平均百分比为70.0（标准差18.2），III级为81.3（16.5），IV级为85.0（13.6）。然后我们将生存素指数与MIB-1指数进行比较，发现在低级别胶质瘤（II级和III级）中，高生存素指数和低生存素指数之间的生存时间差异显著（P = 0.007），而高MIB-1指数和低MIB-1指数之间的差异不显著（P = 0.092）。结论：在评估低级别胶质瘤方面，生存素比MIB-1更敏感，因为它有助于预测患者的生存情况。需要更大规模的胶质瘤患者系列来验证我们这项有限研究的结果。
